Comparison of Two Treatment Modalities in Overactive Bladder: A Rapid Overview

Med Arch. 2022 Dec;76(6):469-472. doi: 10.5455/medarh.2022.76.469-472.

Abstract

Background: Overactive bladder is a syndrome of urgency with the absence of infection and is usually accompanied by frequency and nocturia. Both sacral neuromodulation (SNM) and intravesical botulinum toxin (BTX) injection are used contentiously in overactive bladder after failure of conservative management.

Objective: We aimed to provide an updated comparative overview of BTX injection versus SNM in the treatment of overactive bladder.

Methods: PubMed and Google scholar databases were explored starting from 2016 to 2022 to obtain relevant articles. English studies on adult population were included.

Results: Six articles included 648 participants were included in the current overview. Both BTX and SNM are comparable for the treatment of overactive bladder, with no major complications were reported. However, the use of SNM for refractory overactive bladder after failure of BTX was more successful and effective and resulted in patient satisfaction compared to the use of BTX after failure of SNM.

Conclusion: Our update provides the latest comparative overview of outcomes of BTX versus SNM in the treatment of overactive bladder.

Keywords: Botulinum Toxins; Review; Urinary Incontinence.

Publication types

  • Review

MeSH terms

  • Adult
  • Botulinum Toxins, Type A* / therapeutic use
  • Electric Stimulation Therapy* / methods
  • Humans
  • Patient Satisfaction
  • Sacrum
  • Treatment Outcome
  • Urinary Bladder, Overactive* / drug therapy

Substances

  • Botulinum Toxins, Type A